TOLTERODINE TARTRATE

Tolterodine Tartrate Adverse Events Reported to the FDA Over Time

How are Tolterodine Tartrate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Tolterodine Tartrate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Tolterodine Tartrate is flagged as the suspect drug causing the adverse event.

Most Common Tolterodine Tartrate Adverse Events Reported to the FDA

What are the most common Tolterodine Tartrate adverse events reported to the FDA?

Drug Ineffective	1034 (6.24%)
Dry Mouth	570 (3.44%)
Constipation	325 (1.96%)
Pollakiuria	267 (1.61%)
Dizziness	256 (1.55%)
Urinary Incontinence	245 (1.48%)
Urinary Retention	176 (1.06%)
Drug Effect Decreased	167 (1.01%)
Fall	163 (.98%)
Vision Blurred	150 (.91%)
Condition Aggravated	145 (.88%)
	Show More
Headache	144 (.87%)
Death	138 (.83%)
Nocturia	138 (.83%)
Dysuria	136 (.82%)
Hypertension	134 (.81%)
Pain	133 (.8%)
Diarrhoea	126 (.76%)
Fatigue	124 (.75%)
Weight Decreased	122 (.74%)
Nausea	120 (.72%)
Confusional State	118 (.71%)
Insomnia	112 (.68%)
Drug Interaction	111 (.67%)
Oedema Peripheral	109 (.66%)
Abdominal Pain Upper	108 (.65%)
Bladder Disorder	105 (.63%)
Blood Pressure Increased	103 (.62%)
Urinary Tract Infection	102 (.62%)
Malaise	101 (.61%)
Micturition Urgency	94 (.57%)
Vomiting	92 (.56%)
Dry Eye	89 (.54%)
Hypertonic Bladder	86 (.52%)
Cystitis	82 (.49%)
Abdominal Pain	78 (.47%)
Somnolence	78 (.47%)
Weight Increased	78 (.47%)
Feeling Abnormal	77 (.46%)
Blood Cholesterol Increased	74 (.45%)
Rash	72 (.43%)
Loss Of Consciousness	71 (.43%)
Asthenia	67 (.4%)
Glaucoma	67 (.4%)
Cerebrovascular Accident	66 (.4%)
Hypersensitivity	66 (.4%)
Dyspnoea	65 (.39%)
Memory Impairment	65 (.39%)
Arthritis	64 (.39%)
Depression	64 (.39%)
Amnesia	63 (.38%)
Dehydration	61 (.37%)
Dyspepsia	61 (.37%)
Pain In Extremity	61 (.37%)
Pruritus	61 (.37%)
Chest Pain	57 (.34%)
Dysphagia	57 (.34%)
Back Pain	56 (.34%)
Incontinence	56 (.34%)
Muscle Spasms	54 (.33%)
Gastrooesophageal Reflux Disease	53 (.32%)
Heart Rate Increased	53 (.32%)
Tremor	53 (.32%)
Gait Disturbance	52 (.31%)
Blood Glucose Increased	50 (.3%)
Incorrect Dose Administered	50 (.3%)
Pneumonia	50 (.3%)
Cataract	49 (.3%)
Treatment Noncompliance	49 (.3%)
Arthralgia	48 (.29%)
Myocardial Infarction	48 (.29%)
Surgery	48 (.29%)
Abdominal Distension	47 (.28%)
Convulsion	44 (.27%)
Disorientation	43 (.26%)
Dry Throat	42 (.25%)
Body Height Decreased	41 (.25%)
Completed Suicide	41 (.25%)
Abasia	40 (.24%)
Abdominal Discomfort	40 (.24%)
Cardiac Disorder	40 (.24%)
Balance Disorder	39 (.24%)
Post Procedural Complication	39 (.24%)
Bladder Pain	38 (.23%)
Diabetes Mellitus	38 (.23%)
Sleep Disorder	37 (.22%)
Decreased Appetite	36 (.22%)
Fluid Retention	36 (.22%)
Hypotension	36 (.22%)
Hallucination	35 (.21%)
Road Traffic Accident	35 (.21%)
Unevaluable Event	35 (.21%)
Atrial Fibrillation	34 (.21%)
Flatulence	34 (.21%)
Anxiety	33 (.2%)
Visual Acuity Reduced	33 (.2%)
Joint Injury	32 (.19%)
Nervousness	32 (.19%)
Tachycardia	32 (.19%)
Bladder Operation	31 (.19%)
Bladder Spasm	31 (.19%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Tolterodine Tartrate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tolterodine Tartrate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Tolterodine Tartrate

What are the most common Tolterodine Tartrate adverse events reported to the FDA?

Therapeutic And Nontherapeutic Effe...	1391 (8.4%)
Urinary Tract Signs	1310 (7.91%)
Neurological	748 (4.51%)
Gastrointestinal Signs	729 (4.4%)
Salivary Gland Conditions	583 (3.52%)
Gastrointestinal Motility And Defec...	537 (3.24%)
Infections - Pathogen Unspecified	411 (2.48%)
Epidermal And Dermal Conditions	353 (2.13%)
Injuries	348 (2.1%)
Respiratory	306 (1.85%)
Vision	282 (1.7%)
	Show More
Bladder And Bladder Neck Disorders	260 (1.57%)
Cardiac And Vascular Investigations	258 (1.56%)
Physical Examination Topics	255 (1.54%)
Musculoskeletal And Connective Tiss...	247 (1.49%)
Medication Errors	233 (1.41%)
Mental Impairment	203 (1.23%)
Joint	198 (1.2%)
Sleep Disorders	191 (1.15%)
Deliria	183 (1.1%)
Bone And Joint Injuries	181 (1.09%)
Eye	168 (1.01%)
Headaches	164 (.99%)
Cardiac Arrhythmias	152 (.92%)
Muscle	148 (.89%)
Electrolyte And Fluid Balance Condi...	145 (.88%)
Vascular Hypertensive	145 (.88%)
Fatal Outcomes	141 (.85%)
Lifestyle Issues	136 (.82%)
Anxiety Disorders	123 (.74%)
Renal Disorders	120 (.72%)
Allergic Conditions	115 (.69%)
Central Nervous System Vascular	108 (.65%)
Hematology Investigations	106 (.64%)
Movement Disorders	106 (.64%)
Lipid Analyses	103 (.62%)
Metabolic, Nutritional And Blood Ga...	98 (.59%)
Upper Respiratory Tract Disorders	91 (.55%)
Renal And Urinary Tract Investigati...	87 (.53%)
Appetite And General Nutritional	84 (.51%)
Bone And Joint Therapeutic Procedur...	84 (.51%)
Therapeutic Procedures And Supporti...	84 (.51%)
Glaucoma And Ocular Hypertension	79 (.48%)
Cardiac Disorder Signs	77 (.46%)
Seizures	77 (.46%)
Skin Appendage Conditions	77 (.46%)
Depressed Mood Disorders	74 (.45%)
Decreased And Nonspecific Blood Pre...	73 (.44%)
Coronary Artery	72 (.43%)
Disturbances In Thinking	72 (.43%)
Oral Soft Tissue Conditions	72 (.43%)
Procedural And Device Related Injur...	71 (.43%)
Suicidal And Self-injurious Behavio...	69 (.42%)
Water, Electrolyte And Mineral	67 (.4%)
Bacterial Infectious	58 (.35%)
Hearing	55 (.33%)
Renal And Urinary Tract Therapeutic...	54 (.33%)
Anterior Eye Structural Change, Dep...	51 (.31%)
Gastrointestinal Conditions	51 (.31%)
Glucose Metabolism Disorders	50 (.3%)
Hepatobiliary	48 (.29%)
Psychiatric	47 (.28%)
Vulvovaginal Disorders	46 (.28%)
Ocular Infections, Irritations And ...	44 (.27%)
Viral Infectious	42 (.25%)
Chemical Injury And Poisoning	41 (.25%)
Gastrointestinal Stenosis And Obstr...	41 (.25%)
Bone Disorders	40 (.24%)
Tongue Conditions	40 (.24%)
Eye Therapeutic Procedures	38 (.23%)
Heart Failures	38 (.23%)
Lower Respiratory Tract Disorders	38 (.23%)
Mood Disorders	38 (.23%)
Inner Ear And Viiith Cranial Nerve	37 (.22%)
Angiedema And Urticaria	36 (.22%)
Hepatic And Hepatobiliary	35 (.21%)
Ocular Structural Change, Deposit A...	34 (.21%)
Vascular Hemorrhagic	34 (.21%)
Personality Disorders	33 (.2%)
Vascular	32 (.19%)
Arteriosclerosis, Stenosis, Vascula...	31 (.19%)
Male Genital Tract Therapeutic Proc...	30 (.18%)
Neuromuscular	30 (.18%)
Anemias Nonhemolytic And Marrow Dep...	29 (.18%)
Bronchial Disorders	29 (.18%)
Cardiac Therapeutic Procedures	29 (.18%)
Dental And Gingival Conditions	29 (.18%)
Gastrointestinal Therapeutic Proced...	29 (.18%)
Uterine, Pelvic And Broad Ligament	29 (.18%)
Gastrointestinal Hemorrhages	28 (.17%)
Gastrointestinal Ulceration And Per...	28 (.17%)
Respiratory And Mediastinal Neoplas...	28 (.17%)
Urolithiases	28 (.17%)
Body Temperature Conditions	25 (.15%)
Obstetric And Gynecological Therape...	25 (.15%)
Thyroid Gland	25 (.15%)
Tissue	25 (.15%)
Peripheral Neuropathies	24 (.14%)
Psychiatric And Behavioural Symptom...	24 (.14%)
Gastrointestinal Inflammatory Condi...	23 (.14%)
Musculoskeletal And Connective Tiss...	23 (.14%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Tolterodine Tartrate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tolterodine Tartrate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.